Trabzon Liman Isletmeciligi AS

As of March 31, 2025, Trabzon Liman Isletmeciligi AS carries a market capitalization of 1.89B, placing it among publicly traded companies globally. Its enterprise value stands at 1.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Trabzon Liman Isletmeciligi AS has 21.00M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 3.13, and the price-to-book ratio stands at 1.38.

As of March 31, 2025, Trabzon Liman Isletmeciligi AS trades at an EV/EBITDA multiple of 8.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.38 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.66B versus a market cap of 1.89B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2025, Trabzon Liman Isletmeciligi AS maintains a current ratio of 5.29, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.14, indicating elevated leverage, while an interest coverage ratio of 16.03 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Trabzon Liman Isletmeciligi AS posted a negative return on equity (ROE) of -4.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.72, reflecting losses generated across the asset base. Inventory turnover of 174.29 indicates how many times Trabzon Liman Isletmeciligi AS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2025, Trabzon Liman Isletmeciligi AS recorded 51.90M in income tax expense. The company reported a pretax loss of -4.32M and -56.21M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Trabzon Liman Isletmeciligi AS's stock has declined approximately 47.35% over the past 52 weeks. The 50-day moving average sits at 70.40, while the 200-day moving average is 87.48.

Over the twelve months ended March 31, 2025, Trabzon Liman Isletmeciligi AS generated 603.13M in revenue and converted that into -56.21M in net income, yielding earnings per share of -2.68. EBITDA reached 194.30M, while operating income came in at 87.92M.

As of March 31, 2025, Trabzon Liman Isletmeciligi AS holds 358.94M in cash and equivalents against 125.30M in total debt, resulting in a net debt position of 119.54M. Total book value stands at 1.37B, with working capital of 438.02M providing operational flexibility.

Trabzon Liman Isletmeciligi AS produced 323.18M in operating cash flow over the twelve months ended March 31, 2025. After subtracting -325.00M in capital expenditures, free cash flow totaled -1.82M - equivalent to -0.09 per share.

Over the twelve months ended March 31, 2025, Trabzon Liman Isletmeciligi AS posted a gross margin of 21.38, reflecting its pricing power and cost economics. The operating margin of 14.58 and net profit margin of -9.32 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -0.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Trabzon Liman Isletmeciligi AS shareholders.

As of March 31, 2025, Trabzon Liman Isletmeciligi AS has an Altman Z-Score of 4.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.